ENXTPA:SANPharmaceuticals
Sanofi R&D Reset Amlitelimab Gene Therapy And Vaccines Reframe Growth
Sanofi reported positive late stage results for amlitelimab in atopic dermatitis, pointing to a potential new high-value asset alongside Dupixent.
The company increased its gene therapy exposure with a sizeable investment in Sensorion, expanding its pipeline into genetic medicines.
Recent acquisitions of Vicebio and Dynavax strengthened Sanofi's vaccines portfolio at a time of external pressure in vaccine markets.
For investors watching ENXTPA:SAN, these R&D moves arrive after a challenging...